Physician profile
Devin Talor Smith
NPI 1407575830
$2,501.99
in general payments reported to CMS, 2019-2025
28 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $794 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.99 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $285.60 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $248.40 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $218.08 | 2024-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $206.99 | 2024-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $162.00 | 2024-2025 | Wegovy, Ozempic |
| Bridgebio Pharma, INC. | $161.34 | 2025 | Attruby |
| United Therapeutics Corporation | $139.35 | 2024-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $133.02 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $119.39 | 2024-2025 | Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $106.75 | 2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.19 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.58 | 2024-2025 | Lifevest |
| Providence Medical Technology, INC. | $86.74 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.35 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $61.63 | 2025 | Edarbi, Edarbyclor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $46.36 | 2024 | |
| Pfizer INC. | $41.58 | 2024-2025 | |
| Baxter Healthcare | $39.94 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $30.37 | 2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $28.77 | 2024 | Arcalyst |
| Medtronic, INC. | $24.77 | 2024 | Corevalve Evolut R |
| Vital Connect, INC | $20.47 | 2025 | Vitalpatch Rtm |
| Inspire Medical Systems, INC. | $19.18 | 2025 | Inspire |
| Mannkind Corporation | $17.94 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.40 | 2024 | |
| Cvrx, INC. | $16.80 | 2025 | Barostim Neo System |
| Glaxosmithkline, LLC. | $14.81 | 2025 | Shingrix, Arexvy |
| Ossur Americas, INC. | $7.19 | 2024 | Miami J |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.